Ginkgo Bioworks Holdings, Inc. DNA
NYSE
| 09/30/2026 | 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 12.26% | 43.44% | -2.27% | 0.00% | -33.92% |
| Total Depreciation and Amortization | -4.59% | -4.47% | -4.06% | -5.89% | -13.80% |
| Total Amortization of Deferred Charges | 2.44% | -2.38% | -10.64% | 14.63% | -2.38% |
| Total Other Non-Cash Items | 375.58% | -91.23% | -13.30% | 75.91% | -15.51% |
| Change in Net Operating Assets | -13.68% | 7.28% | 39.89% | -312.82% | 145.92% |
| Cash from Operations | 35.97% | 5.17% | 2.08% | -50.85% | 21.48% |
| Capital Expenditure | 23.63% | -35.49% | -38,560.00% | -- | 100.00% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -261.25% | -45.32% | -73.48% | 229.82% | -14.04% |
| Cash from Investing | -317.38% | -52.07% | -75.68% | 230.60% | -13.97% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | 100.00% | 24.00% | -4.17% | 75.51% |
| Issuance of Common Stock | -60.43% | -- | -- | -11.29% | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 56.79% | -- | -- | -177.46% | -- |
| Cash from Financing | -60.56% | 86,884.21% | -100.23% | -18.07% | 10,240.82% |
| Foreign Exchange rate Adjustments | -86.05% | 133.33% | 15.13% | -263.44% | -50.00% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -175.84% | 29.74% | -142.77% | 158.70% | 9.29% |